Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid plus maximal androgen blockade in newly diagnosed bone metastatic prostate cancer
ChiCTR-ONRC-13004145Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of zoledronic acid in prostate cancer (PCa) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Skeletal-related event-free survival and Overall survival. Started Nov 2013; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR-ONRC-13004145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-13004145.